SCHEDULE 13D/A: Saba Capital Amends Stake in abrdn Life Sciences Investors, Discloses Recent Share Sales
Ownership Disclosure Amendment
Saba Capital Management, L.P. and its affiliates filed an Amendment No. 6 to their Schedule 13D, disclosing a continued beneficial ownership of 11.36% in abrdn Life Sciences Investors and detailing recent share sales.
Summary
- Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein (collectively, the "Reporting Persons") have filed an Amendment No. 6 to their Schedule 13D regarding their beneficial ownership in abrdn Life Sciences Investors.
- The Reporting Persons collectively beneficially own 3,188,405 Common Shares of abrdn Life Sciences Investors, representing 11.36% of the class.
- This percentage is calculated based on 28,061,399 shares of common stock outstanding as of September 30, 2024, as disclosed in the company's N-CSR filed on December 9, 2024.
- Approximately $41,813,585 was paid to acquire the Common Shares reported in this filing.
- Funds for the share purchases were derived from subscription proceeds from investors, capital appreciation, and margin account borrowings.
- Between January 30, 2025, and March 31, 2025, Saba Capital effectuated multiple open market sales of Common Shares, with prices ranging from $12.58 to $14.27 per share.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of a significant shareholder's updated position and recent trading activity. While the sales indicate some reduction in exposure, the overall beneficial ownership remains substantial (11.36%), suggesting continued interest.
Positives
- Saba Capital maintains a significant beneficial ownership stake of 11.36% in abrdn Life Sciences Investors, indicating continued substantial interest in the company.
Negatives
- Saba Capital has engaged in multiple open market sales of abrdn Life Sciences Investors' Common Shares over the past two months, which could signal a partial reduction in their position or a less bullish outlook at current price levels.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May interpret Saba Capital's recent sales as a signal, potentially influencing market sentiment or the company's share price.
Key Dates
| Date | Description |
|---|---|
| 2015-11-16 | Date of power of attorney for authorized signatory. |
| 2015-12-28 | Date Schedule 13G was filed by the Reporting Persons. |
| 2024-09-30 | Date as of which 28,061,399 common shares were outstanding, used for percentage calculation. |
| 2024-12-09 | Date abrdn Life Sciences Investors' N-CSR was filed, disclosing shares outstanding. |
| 2025-01-30 | First reported sale transaction date by Saba Capital. |
| 2025-03-31 | Date of event which required filing of this statement; last reported sale transaction date. |
| 2025-04-01 | Signature date of the Schedule 13D/A filing. |
Recommendation
holdKeywords
abrdn Life Sciences Investors, Saba Capital Management, Schedule 13D, beneficial ownership, investment fund, life sciences, common shares, SEC filing, share sales
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.